

Paolo Marzullo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8720101/publications.pdf>

Version: 2024-02-01

172
papers

9,216
citations

36203

51
h-index

45213

90
g-index

179
all docs

179
docs citations

179
times ranked

7361
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic Tests in Pituitary Endocrinology: Pitfalls in Interpretation during Aging. <i>Neuroendocrinology</i> , 2022, 112, 1-14.	1.2	7
2	Aging and comorbidities influence the risk of hospitalization and mortality in diabetic patients experiencing severe hypoglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 160-166.	1.1	5
3	Breast Cancer Diet – A Review of Healthy Dietary Patterns to Prevent Breast Cancer Recurrence and Reduce Mortality. <i>Nutrients</i> , 2022, 14, 476.	1.7	14
4	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1465-1481.	1.8	6
5	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1587-1598.	1.8	10
6	Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma. <i>Endocrine</i> , 2021, 71, 149-157.	1.1	10
7	Exploring extra dimensions to capture saliva metabolite fingerprints from metabolically healthy and unhealthy obese patients by comprehensive two-dimensional gas chromatography featuring Tandem Ionization mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 403-418.	1.9	14
8	Insights into non-classic and emerging causes of hypopituitarism. <i>Nature Reviews Endocrinology</i> , 2021, 17, 114-129.	4.3	24
9	Stimulated GH levels during the transition phase in Prader-Willi syndrome. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1465-1474.	1.8	7
10	Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1447-1456.	1.8	5
11	Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. <i>JAMA Network Open</i> , 2021, 4, e2036142.	2.8	336
12	Neuroinflammation and Hypothalamo-Pituitary Dysfunction: Focus of Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2686.	1.8	15
13	Playing around the anaerobic threshold during COVID-19 pandemic: advantages and disadvantages of adding bouts of anaerobic work to aerobic activity in physical treatment of individuals with obesity. <i>Acta Diabetologica</i> , 2021, 58, 1329-1341.	1.2	4
14	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	24
15	Low-Intensity Whole-Body Vibration: A Useful Adjuvant in Managing Obesity? A Pilot Study. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 5101.	1.3	0
16	Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity. <i>Frontiers in Endocrinology</i> , 2021, 12, 687918.	1.5	1
17	Spot-light on microbiota in obesity and cancer. <i>International Journal of Obesity</i> , 2021, 45, 2291-2299.	1.6	10
18	Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. <i>Biomolecules</i> , 2021, 11, 125.	1.8	27

#	ARTICLE	IF	CITATIONS
19	Obesity and Bone Loss at Menopause: The Role of Sclerostin. <i>Diagnostics</i> , 2021, 11, 1914.	1.3	5
20	Gestational Diabetes Mellitus: Clinical Characteristics and Perinatal Outcomes in a Multiethnic Population of North Italy. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-10.	0.6	5
21	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. <i>International Journal of Obesity Supplements</i> , 2020, 10, 35-49.	12.5	40
22	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 20731.	1.6	96
23	Is Caloric Restriction Associated with Better Healthy Aging Outcomes? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2020, 12, 2290.	1.7	25
24	Fat-Free Mass Is Better Related to Serum Uric Acid Than Metabolic Homeostasis in Prader-Willi Syndrome. <i>Nutrients</i> , 2020, 12, 2583.	1.7	5
25	Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4527-e4530.	1.8	12
26	Immunomodulatory Effects of Vitamin D in Thyroid Diseases. <i>Nutrients</i> , 2020, 12, 1444.	1.7	39
27	The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC). <i>European Journal of Clinical Nutrition</i> , 2020, 74, 1038-1046.	1.3	4
28	Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases. <i>Nutrients</i> , 2020, 12, 789.	1.7	36
29	Irisin levels in genetic and essential obesity: clues for a potential dual role. <i>Scientific Reports</i> , 2020, 10, 1020.	1.6	25
30	Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy. <i>Endocrine</i> , 2020, 69, 107-112.	1.1	17
31	Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. <i>Frontiers in Endocrinology</i> , 2020, 11, 591501.	1.5	23
32	Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 397-402.	1.8	28
33	Vitamin D as a Biomarker of Ill Health among the Over-50s: A Systematic Review of Cohort Studies. <i>Nutrients</i> , 2019, 11, 2384.	1.7	23
34	Altered temporal sensitivity in obesity is linked to pro-inflammatory state. <i>Scientific Reports</i> , 2019, 9, 15508.	1.6	6
35	Levothyroxine Replacement in Obese Adults: The Role of Metabolic Variables and Aging on Thyroid Testing Abnormalities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6265-6274.	1.8	8
36	Assessment of fat-free mass from bioelectrical impedance analysis in men and women with Prader-Willi syndrome: cross-sectional study. <i>International Journal of Food Sciences and Nutrition</i> , 2019, 70, 645-649.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Clinical picture and the treatment of TBI-induced hypopituitarism. <i>Pituitary</i> , 2019, 22, 261-269.	1.6	16
38	The lullaby of the sun: the role of vitamin D in sleep disturbance. <i>Sleep Medicine</i> , 2019, 54, 262-265.	0.8	71
39	Circulating adipokines and metabolic setting in differentiated thyroid cancer. <i>Endocrine Connections</i> , 2019, 8, 997-1006.	0.8	12
40	Non-surgical ablative therapies for inoperable benign insulinoma. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 153-162.	1.8	22
41	Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life. <i>Hormones</i> , 2018, 16, 396-404.	0.9	1
42	Transsphenoidal surgery for pituitary adenomas: early results from a single center. <i>Hormones</i> , 2018, 17, 551-556.	0.9	7
43	Plasma Oxytocin Concentration in Pre- and Postmenopausal Women: Its Relationship with Obesity, Body Composition and Metabolic Variables. <i>Obesity Facts</i> , 2018, 11, 429-439.	1.6	22
44	The relationship between resting energy expenditure and thyroid hormones in response to short-term weight loss in severe obesity. <i>PLoS ONE</i> , 2018, 13, e0205293.	1.1	20
45	Thyroid cancer phenotypes in relation to inflammation and autoimmunity. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 2267-2282.	3.0	19
46	Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. <i>Nutrition Research Reviews</i> , 2018, 31, 291-301.	2.1	90
47	Analysis of Predictive Equations for Estimating Resting Energy Expenditure in a Large Cohort of Morbidly Obese Patients. <i>Frontiers in Endocrinology</i> , 2018, 9, 367.	1.5	23
48	Serum uric acid potentially links metabolic health to measures of fuel use in lean and obese individuals. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1029-1035.	1.1	11
49	New Insights on Low Vitamin D Plasma Concentration as a Potential Cardiovascular Risk Factor.. <i>Open Rheumatology Journal</i> , 2018, 12, 261-278.	0.1	2
50	Growth hormone disorders in adults. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 1-2.	2.2	2
51	Circulating angiopoietin-like 8 (ANGPTL8) is a marker of liver steatosis and is negatively regulated by Prader-Willi Syndrome. <i>Scientific Reports</i> , 2017, 7, 3186.	1.6	15
52	Vitamin D and Neurological Diseases: An Endocrine View. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2482.	1.8	160
53	Acute Vitamin D3 Supplementation in Severe Obesity: Evaluation of Multimeric Adiponectin. <i>Nutrients</i> , 2017, 9, 459.	1.7	18
54	Growth hormone deficiency in children. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 677-678.	2.2	1

#	ARTICLE	IF	CITATIONS
55	The impact of the metabolic phenotype on thyroid function in obesity. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 59.	1.2	13
56	Diagnosis and treatment of GH deficiency in Prader-Willi syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 785-794.	2.2	41
57	Altered multisensory temporal integration in obesity. <i>Scientific Reports</i> , 2016, 6, 28382.	1.6	35
58	Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS). <i>Endocrine</i> , 2016, 52, 441-450.	1.1	22
59	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. <i>Endocrine</i> , 2016, 53, 551-557.	1.1	8
60	Inherent insulin sensitivity is a major determinant of multimeric adiponectin responsiveness to short-term weight loss in extreme obesity. <i>Scientific Reports</i> , 2015, 4, 5803.	1.6	8
61	Growth hormone deficiency in treated acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 11-21.	3.1	20
62	Leptin Level Lowers in Proportion to the Amount of Aerobic Work After Four Weeks of Training in Obesity. <i>Hormone and Metabolic Research</i> , 2015, 47, 225-231.	0.7	10
63	One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. <i>Endocrine</i> , 2015, 50, 620-626.	1.1	50
64	Long-term Echocardiographic and Cardioscintigraphic Effects of Growth Hormone Treatment in Adults With Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2106-2114.	1.8	14
65	Diabetes in Growth Hormone Deficiency. <i>Frontiers in Diabetes</i> , 2014, , 10-21.	0.4	2
66	Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. <i>Cardiovascular Diabetology</i> , 2014, 13, 57.	2.7	36
67	The pathophysiology of abdominal adipose tissue depots in health and disease. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2014, 19, 57-74.	0.3	65
68	Lymphocytes and immunoglobulin patterns across the threshold of severe obesity. <i>Endocrine</i> , 2014, 45, 392-400.	1.1	18
69	MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. <i>European Journal of Endocrinology</i> , 2014, 171, R137-R152.	1.9	174
70	Obesity modifies expression profiles of metabolic markers in superficial and deep subcutaneous abdominal adipose tissue depots. <i>Endocrine</i> , 2014, 46, 99-106.	1.1	24
71	Short bouts of anaerobic exercise increase non-esterified fatty acids release in obesity. <i>European Journal of Nutrition</i> , 2014, 53, 243-249.	1.8	13
72	Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism. <i>Growth Hormone and IGF Research</i> , 2013, 23, 109-113.	0.5	24

#	ARTICLE	IF	CITATIONS
73	THERAPY OF ENDOCRINE DISEASE: GH therapy in adult GH deficiency: A review of treatment schedules and the evidence for low starting doses. <i>European Journal of Endocrinology</i> , 2013, 168, R55-R66.	1.9	26
74	Cocaine Abuse and Sleep Apnea in Severe Obesity. <i>Journal of Addiction Medicine</i> , 2013, 7, 294-295.	1.4	2
75	Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in P/W illi adults and obese controls. <i>Clinical Endocrinology</i> , 2013, 79, 224-231.	1.2	13
76	Clinical pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara. <i>Endocrine</i> , 2012, 42, 382-390.	1.1	18
77	Hypopituitarism following brain injury: when does it occur and how best to test?. <i>Pituitary</i> , 2012, 15, 20-24.	1.6	46
78	Thyroid incidentaloma identified by ¹⁸ F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance. <i>Clinical Endocrinology</i> , 2011, 75, 528-534.	1.2	53
79	Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 493-7.	1.8	13
80	Dynamics of GH secretion during incremental exercise in obesity, before and after a short period of training at different work-loads. <i>Clinical Endocrinology</i> , 2010, 73, no-no.	1.2	12
81	Investigations of Thyroid Hormones and Antibodies in Obesity: Leptin Levels Are Associated with Thyroid Autoimmunity Independent of Bioanthropometric, Hormonal, and Weight-Related Determinants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3965-3972.	1.8	173
82	Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2009, 149A, 726-731.	0.7	16
83	Sagittal abdominal diameter is more predictive of cardiovascular risk than abdominal fat compartments in severe obesity. <i>International Journal of Obesity</i> , 2009, 33, 233-238.	1.6	19
84	Subcutaneous Abdominal Adipose Tissue Subcompartments: Potential Role in Rosiglitazone Effects. <i>Obesity</i> , 2008, 16, 1983-1991.	1.5	41
85	Acyated ghrelin decreases during acute exercise in the lean and obese state. <i>Clinical Endocrinology</i> , 2008, 69, 970-971.	1.2	36
86	Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 765-772.	1.8	37
87	Conditional Cardiovascular Response to Growth Hormone Therapy in Adult Patients with Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1364-1371.	1.8	29
88	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3854-3860.	1.8	56
89	NT-proBNP, IGF-I and survival in patients with chronic heart failure. <i>Growth Hormone and IGF Research</i> , 2007, 17, 288-296.	0.5	51
90	Deep Subcutaneous Adipose Tissue: A Distinct Abdominal Adipose Depot. <i>Obesity</i> , 2007, 15, 1933-1943.	1.5	97

#	ARTICLE	IF	CITATIONS
91	Predictors of Postabsorptive Ghrelin Secretion after Intake of Different Macronutrients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4124-4130.	1.8	31
92	Lack of association between the tetranucleotide repeat polymorphism in the 3' flanking region of the leptin gene and hypertension in severely obese patients. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 776-780.	1.8	6
93	Evaluation of a Multisensor Armband in Estimating Energy Expenditure in Obese Individuals. <i>Obesity</i> , 2006, 14, 2217-2223.	1.5	96
94	Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. <i>Clinical Endocrinology</i> , 2006, 65, 492-499.	1.2	42
95	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. <i>Clinical Endocrinology</i> , 2005, 63, 342-349.	1.2	25
96	Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. <i>Journal of Gastroenterology</i> , 2005, 40, 833-835.	2.3	56
97	The Impact of Growth Hormone/Insulin-Like Growth Factor-I Axis and Nocturnal Breathing Disorders on Cardiovascular Features of Adult Patients with Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5639-5646.	1.8	42
98	Abdominal fat index by ultrasound does not estimate the metabolic risk factors of cardiovascular disease better than waist circumference in severe obesity. <i>Diabetes and Metabolism</i> , 2005, 31, 471-477.	1.4	13
99	Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 440-448.	1.8	63
100	The Relationship between Active Ghrelin Levels and Human Obesity Involves Alterations in Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 936-939.	1.8	160
101	Acromegalic Axial Arthropathy: A Clinical Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 598-603.	1.8	71
102	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. <i>Endocrine Reviews</i> , 2004, 25, 102-152.	8.9	1,093
103	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003, 58, 169-176.	1.2	99
104	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3196-3201.	1.8	119
105	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. <i>European Journal of Endocrinology</i> , 2003, 148, 31-38.	1.9	55
106	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2002, 146, 303-309.	1.9	63
107	Early Vascular Alterations in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3174-3179.	1.8	100
108	Acromegaly and immune function. <i>NeuroImmune Biology</i> , 2002, , 247-257.	0.2	3

#	ARTICLE	IF	CITATIONS
109	Lymphocyte subset pattern in acromegaly. Journal of Endocrinological Investigation, 2002, 25, 125-128.	1.8	21
110	Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. Journal of Endocrinological Investigation, 2002, 25, 971-976.	1.8	77
111	Leptin Concentrations in GH Deficiency: The Effect of GH Insensitivity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 540-545.	1.8	21
112	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clinical Endocrinology, 2002, 56, 153-158.	1.2	67
113	Trattamento dell'acromegalia: attualità e prospettive. L Endocrinologo, 2001, 2, 99-109.	0.0	0
114	Growth hormone and the heart. Clinical Endocrinology, 2001, 54, 137-154.	1.2	328
115	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology, 2001, 54, 515-524.	1.2	101
116	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2779-2786.	1.8	242
117	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3001-3008.	1.8	84
118	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	1.8	102
119	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	1.8	81
120	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2779-2786.	1.8	214
121	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3001-3008.	1.8	67
122	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 2000, 53, 53-60.	1.2	77
123	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology, 2000, 53, 13-19.	1.2	52
124	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 193-199.	1.8	154
125	Cardiac Effect of Thyrotoxicosis in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1426-1432.	1.8	17
126	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3754-3761.	1.8	38

#	ARTICLE	IF	CITATIONS
127	Muscle Sympathetic Nerve Activity in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3203-3207.	1.8	14
128	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4099-4103.	1.8	99
129	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3132-3140.	1.8	95
130	New Medical Approaches in Pituitary Adenomas. <i>Hormone Research in Paediatrics</i> , 2000, 53, 76-87.	0.8	42
131	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. <i>European Journal of Endocrinology</i> , 2000, 143, 61-69.	1.9	16
132	Acromegaly and prostate cancer. <i>Growth Hormone and IGF Research</i> , 2000, 10, S37-S38.	0.5	7
133	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 193-199.	1.8	123
134	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3754-3761.	1.8	35
135	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4099-4103.	1.8	83
136	Cardiac Effect of Thyrotoxicosis in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1426-1432.	1.8	15
137	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3132-3140.	1.8	75
138	Impact of Patient's Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1518-1523.	1.8	71
139	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2664-2672.	1.8	344
140	Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 17-23.	1.8	115
141	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	1.8	67
142	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. <i>Clinical Endocrinology</i> , 1999, 51, 159-164.	1.2	21
143	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , 1999, 51, 611-618.	1.2	64
144	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999, 1, 115-120.	1.6	81

#	ARTICLE	IF	CITATIONS
145	The pituitary uptake of ¹¹¹ In-DTPA-D-Phe ¹ -octreotide in the normal pituitary and in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 176-183.	1.8	42
146	Percutaneous ethanol injection under Power Doppler ultrasound assistance in the treatment of autonomously functioning thyroid nodules. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 752-759.	1.8	16
147	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 40-47.	1.8	65
148	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Urology</i> , 1998, 160, 1583-1584.	0.2	0
149	Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2121-2125.	1.8	70
150	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 775-779.	1.8	94
151	Prostatic Hyperplasia in Patients with Acromegaly—Authors'™ Response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2606-a-2607.	1.8	3
152	Effect of Different Dopaminergic Agents in the Treatment of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 518-523.	1.8	140
153	Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3308-3314.	1.8	199
154	Effect of Growth Hormone on Cardiac Function. <i>Hormone Research</i> , 1997, 48, 38-42.	1.8	51
155	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997, 47, 23-28.	1.2	89
156	Cardiovascular aspects in acromegaly: Effects of treatment. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 57-60.	1.5	41
157	Prediction of efficacy of octreotide therapy in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2356-2362.	1.8	25
158	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , 1996, 45, 157-166.	1.2	11
159	Corticotropin Releasing Hormone Administration Increases Alpha-Melanocyte-Stimulating Hormone Levels in the Inferior Petrosal Sinuses in a Subset of Patients with Cushing's Disease. <i>Hormone Research</i> , 1996, 46, 26-32.	1.8	5
160	Prediction of efficacy of octreotide therapy in patients with acromegaly.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2356-2362.	1.8	126
161	Comparison among Different Dopamine-Agonists of New Formulation in the Clinical Management of Macroprolactinomas. <i>Hormone Research</i> , 1995, 44, 222-228.	1.8	21
162	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , 1995, 9, 15-21.	0.7	7

#	ARTICLE	IF	CITATIONS
163	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , 1995, 132, 559-564.	1.9	32
164	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995, 133, 189-194.	1.9	10
165	CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. <i>Biomedicine and Pharmacotherapy</i> , 1994, 48, 167-174.	2.5	7
166	Simultaneous and Bilateral Inferior Petrosal Sinus Sampling for the Diagnosis of Cushing's Syndrome: Comparison of Multihormonal Assay, Baseline Multiple Sampling and ACTH-Releasing Hormone Test. <i>Hormone Research</i> , 1993, 40, 209-216.	1.8	31
167	Effects of a Chronic Treatment with Octreotide in Patients with Functionless Pituitary Adenomas. <i>Hormone Research</i> , 1993, 40, 149-155.	1.8	29
168	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. , 0, .		23
169	Early Vascular Alterations in Acromegaly. , 0, .		20
170	Circulating Irisin in Children and Adolescents With Prader-Willi Syndrome: Relation With Glucose Metabolism. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
171	Bone Response to Weight Loss Following Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
172	Thyrotropic Axis and Disorders of Consciousness in Acquired Brain Injury: A Potential Intriguing Association?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4